Patents by Inventor Jo Van Damme

Jo Van Damme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Patent number: 7338653
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: March 4, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Use of amino-terminally truncated RANTES to inhibit HIV viral replication
    Patent number: 7326411
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: February 5, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated RANTES as chemokine antagonists
    Patent number: 6977071
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: December 20, 2005
    Assignee: Applied Research Systems ARS Holding NV
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated rantes as chemokine antagonists
    Publication number: 20050220790
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 18, 2005
    Publication date: October 6, 2005
    Applicant: Applied Research Systems ARS Holding NV
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Publication number: 20050201977
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 6, 2005
    Publication date: September 15, 2005
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated rantes as chemokine antagonists
    Publication number: 20050164936
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 7, 2005
    Publication date: July 28, 2005
    Applicant: Applied Research Systems ARS Holding NV
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Patent number: 6905676
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: June 14, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Publication number: 20030124677
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 28, 2000
    Publication date: July 3, 2003
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated rantes as chemokine antagonists
    Publication number: 20030119148
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 28, 2000
    Publication date: June 26, 2003
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Granulocyte chemotactic protein
    Patent number: 5840524
    Abstract: This invention is directed to a new family of mammalian chemokine proteins, which have been designated granulocyte chemotactic protein-2 (GCP-2) proteins, and includes mammalian GCP-2, sequence-related variants of mammalian GCP-2, and distinct peptide fragments of GCP-2.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 24, 1998
    Assignee: Stichting Rega vzw
    Inventors: Jo Van Damme, Paul Proost
  • Method for modulating cell apoptosis
    Patent number: 5824551
    Abstract: The invention is based upon the newly recognized ability of .beta. chemokines to inhibit cell apoptosis. In particular, apoptosis of T cells is described. The known .beta. chemokines I-309 and TCA-3 are examples of the .beta. chemokines which inhibit apoptosis. One aspect of the invention is the use of these molecules to inhibit apoptosis. A second aspect of the invention is the use of .beta. chemokine inhibitors or antagonists to provoke apoptosis.
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: October 20, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Jo Van Damme, Paul Proost, Frederic Houssiau, Jean-Christophe Renauld